How much funding has Korro Bio raised?

Korro Bio has raised $159.0M in total funding, most recently a Private Equity round.

Where is Korro Bio headquartered?

Korro Bio is headquartered in Cambridge, Massachusetts, United States.

What industry is Korro Bio in?

Korro Bio operates in Biotech, Healthcare.

How many employees does Korro Bio have?

Korro Bio has 51-200 employees.

Korro Bio

Q: Who are Korro Bio's investors?

Korro Bio's investors include Venrock, New Enterprise Associates, Atlas Venture.

IPO

Edit the message. Rewrite the future.

Public · Cambridge, United States · $159.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Business Model: B2B
Total Funding: $159.0M

Last Round: $85.0M Private EquityNov 2024
Rounds: 3
Type: Public

About

Korro Bio is a clinical-stage biotechnology company pioneering RNA editing to deliver the future of medicine. Founded to turn extraordinary scientific insights into life-altering treatments, Korro harnesses the body's natural RNA editing machinery to make precise, single-base RNA edits that modulate protein function. Its proprietary OPERA® (Oligonucleotide Promoted Editing of RNA) platform enables discovery and development of drug candidates for rare and prevalent diseases. Lead program KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide targeting hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE), with a regulatory filing anticipated in H2 2026. A second program, KRRO-111, targets alpha-1 antitrypsin deficiency (AATD) and achieved over 90% RNA editing in preclinical studies. Korro's mission is to rewrite the future for patients with debilitating diseases by repairing the underlying genetic cause.

Summary

Korro Bio is a Biotech company based in Cambridge, United States. It has raised $159.0M in total across 3 rounds, most recently a $85.0M Private Equity round in Nov 2024. Investors include Venrock, New Enterprise Associates and Atlas Venture.